Sec Form 4 Filing - Mazur Leonard L @ Citius Pharmaceuticals, Inc. - 2025-08-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Mazur Leonard L 2. Issuer Name and Ticker or Trading Symbol Citius Pharmaceuticals, Inc. [ CTXR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 08/08/2025 (Street) CRANFORD, NJ07016 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 410,214 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant to Purchase Common Stock ( 1 ) $ 28.75 08/08/2025 D( 1 ) 125,490 ( 1 ) 08/14/2025 Common Stock 125,490 ( 1 ) 0 D Warrant to Purchase Common Stock ( 1 ) $ 28.75 08/08/2025 A( 1 ) 125,490 ( 1 ) 08/14/2026 Common Stock 125,490 ( 1 ) 125,490 D Warrant to Purchase Common Stock ( 2 ) $ 19.25 08/08/2025 D( 2 ) 89,388 ( 2 ) 09/27/2025 Common Stock 89,388 ( 2 ) 0 D Warrant to Purchase Common Stock ( 2 ) $ 19.25 08/08/2025 A( 2 ) 89,388 ( 2 ) 09/27/2026 Common Stock 89,388 ( 2 ) 89,388 D Stock Option (Right to Purchase Common Stock) $ 9.5 ( 3 ) 11/07/2034 Common Stock 24,000 24,000 D Stock Option (Right to Purchase Common Stock) $ 17.5 ( 4 ) 10/10/2033 Common Stock 22,000 22,000 D Stock Option (Right to Purchase Common Stock) $ 31.25 ( 5 ) 10/04/2032 Common Stock 22,000 22,000 D Stock Option (Right to Purchase Common Stock) $ 51 ( 6 ) 10/11/2031 Common Stock 26,000 26,000 D Stock Option (Right to Purchase Common Stock) $ 50 ( 6 ) 07/22/2031 Common Stock 12,000 12,000 D Stock Option (Right to Purchase Common Stock) $ 25.25 ( 6 ) 10/06/2030 Common Stock 8,000 8,000 D Stock Option (Right to Purchase Common Stock) $ 16.75 ( 6 ) 10/08/2029 Common Stock 7,000 7,000 D Stock Option (Right to Purchase Common Stock) $ 40.5 ( 6 ) 09/04/2028 Common Stock 6,000 6,000 D Stock Option (Right to Purchase Common Stock) $ 86.25 ( 6 ) 09/13/2027 Common Stock 1,600 1,600 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Mazur Leonard L C/O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ07016 X Chief Executive Officer Signatures /s/ Alexander M. Donaldson, by power of attorney 09/23/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. ( 2 )The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. ( 3 )The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. ( 4 )The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. ( 5 )The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. ( 6 )The options are vested in full and exercisable immediately.

Remarks: All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.